68 research outputs found
Клинико-фармакоэкономический анализ антигеликобактерной терапии в стационарных и амбулаторно-поликлинических условиях
ГЕЛИКОБАКТЕРИОЗ /ЛЕК ТЕРЭКОНОМИКА ФАРМАЦЕВТИЧЕСКА
Correction to: Current research into brain barriers and the delivery of therapeutics for neurological diseases: a report on CNS barrier congress London, UK, 2017
After publication of the article [1], it has been brought to our attention that there are some errors in the formatting of names in the final version of the article
On The Rate and Extent of Drug Delivery to the Brain
To define and differentiate relevant aspects of blood–brain barrier transport and distribution in order to aid research methodology in brain drug delivery. Pharmacokinetic parameters relative to the rate and extent of brain drug delivery are described and illustrated with relevant data, with special emphasis on the unbound, pharmacologically active drug molecule. Drug delivery to the brain can be comprehensively described using three parameters: Kp,uu (concentration ratio of unbound drug in brain to blood), CLin (permeability clearance into the brain), and Vu,brain (intra-brain distribution). The permeability of the blood–brain barrier is less relevant to drug action within the CNS than the extent of drug delivery, as most drugs are administered on a continuous (repeated) basis. Kp,uu can differ between CNS-active drugs by a factor of up to 150-fold. This range is much smaller than that for log BB ratios (Kp), which can differ by up to at least 2,000-fold, or for BBB permeabilities, which span an even larger range (up to at least 20,000-fold difference). Methods that measure the three parameters Kp,uu, CLin, and Vu,brain can give clinically valuable estimates of brain drug delivery in early drug discovery programmes
Perspectives on Nanodelivery to the Brain : Prerequisites for Successful Brain Treatment
Nanocarriers (NCs) are promising tools to improve drug delivery across the blood-brain barrier (BBB) for more effective treatment of brain disorders, although there is a scarcity of clinical translation of brain-directed NCs. In order to drive the development of brain-oriented NCs toward clinical success, it is essential to understand the prerequisites for nanodelivery to be successful in brain treatment. In this Perspective, we present how pharmacokinetic/pharmacodynamic (PK/PD), formulation and nanotoxicity factors impact the therapeutic success of brain-specific nanodelivery. Properties including high loading efficiency, slow in vivo drug release, long systemic circulation, an increase in unbound brain-to-plasma concentration/exposure ratio (K-p,K-uu,K-brain), high drug potency, and minimal nanotoxicity are prerequisites that should preferably be combined to maximize the therapeutic potential of a brain-targeted NC. The PK of brain-directed NCs needs to be evaluated in a more therapeutically relevant manner, focusing on the released, unbound drug. It is more crucial to increase the K-p,K-uu,K-brain than to improve the ability of the NC to cross the BBB in its intact form. Brain-targeted NCs, which are mostly developed for treating brain tumors, including metastases, should aim to enhance drug delivery not just to tumor regions with disrupted BBB, but equally important to regions with intact BBB where the drugs themselves have problems reaching. This article provides critical insights into how a brain-targeted nanoformulation needs to be designed and optimized to achieve therapeutic success in the brain
The brain slice method for studying drug distribution in the CNS
The high-throughput brain slice method is a precise and robust technique for estimating the overall uptake of drugs into brain tissue through determination of the unbound volume of distribution in the brain (Vu,brain; ml·g brain-1). Vu,brain describes the relationship between the total drug concentration in the brain and the concentration of unbound drug in the brain interstitial fluid, regardless of blood–brain barrier function. The brain slice method is more physiologically based than the brain homogenate method with respect to the assessment of drug distribution in the brain because the cell-cell interactions, pH gradients and active transport systems are all conserved. The method provides information that is directly relevant to issues such as nonspecific binding to brain tissue, lysosomal trapping, and active uptake into the cells. For these reasons, the brain slice method is recommended for estimation of target-site pharmacokinetics in the early drug discovery process and fundamental pharmacological studies. This article provides a detailed protocol for the rat and mouse brain slice methods, with the aim of enabling simple, cost-effective profiling of compounds with diverse physicochemical properties. The procedure for assessing the viability of the brain slices after the 5 h incubation period is also described. The results are interpreted for a set of compounds covering a wide range of physicochemical properties and various pharmacological targets. Application of the method for evaluating the unbound intracellular-to-extracellular concentration ratio (Kp,uu,cell) and the unbound brain-to-plasma concentration ratio (Kp,uu,brain) is discussed
AND HAMMALUND-UDENAES, M.: Quantification of effect delay and acute tolerance development to morphine in the rat
ABSTRACT ABBREVIATIONS: M3G, morphine-3-glucuronide; M6G, morphine-6-glucuronlde; AUC, area under concentration-tIme curve from time zero to infinity; AUMC, area under the first moment curve from time zero to infinity
Exploring Factors Causing Low Brain Penetration of the Opioid Peptide DAMGO through Experimental Methods and Modeling
To
advance the development of peptide analogues for improved treatment
of pain, we need to learn more about the blood–brain barrier
transport of these substances. A low penetration into the brain, with
an unbound brain to blood ratio, <i>K</i><sub>p,uu</sub>, of 0.08, is an important reason for the lack of effect of the enkephalin
analogue DAMGO (H-Tyr-d-Ala-Gly-MePhe-Gly-ol) according to
earlier findings. The aim of this study was to investigate the role
of efflux transporters, metabolism in the brain, and/or elimination
through interstitial fluid bulk flow for the brain exposure of DAMGO.
The in vivo brain distribution of DAMGO was evaluated using microdialysis
in the rat. Data were analyzed with population modeling which resulted
in a clearance into the brain of 1.1 and an efflux clearance 14 μL/min/g_brain.
The efflux clearance was thus much higher than the bulk flow known
from the literature. Coadministration with the efflux transporter
inhibitors cyclosporin A and elacridar in vivo did not affect <i>K</i><sub>p,uu</sub>. The permeability of DAMGO in the Caco-2
assay was very low, of the same size as mannitol. The efflux ratio
was <2 and not influenced by cyclosporin A or elacridar. These
results indicate that the well-known efflux transporters Pgp and Bcrp
are not responsible for the higher efflux of DAMGO, which opens up
for an important role of other transporters at the BBB
- …